Loading stock data…
Pfizer, Inc. (PFE)
$24.17-0.12 (-0.48%)
Market OpenUpdated 11:03 AM EDT
Pfizer Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pfizer Inc. in the Healthcare sector is trading at $24.18 with a market capitalization of $142.9B. Wall Street consensus targets $29.15 (27 analysts), implying a +20.6% move over the next 12 months. The stock is currently near its 52-week low of $23.11, remaining 4.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +20.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.45B↓ | $17.56B↑ | $16.65B↑ | $14.65B↑ | $13.71B |
| Gross Profit | $10.90B↓ | $12.29B↓ | $12.48B↑ | $10.88B | $10.87B |
| Operating Income | $4.13B↑ | $3.48B↓ | $4.14B↑ | $3.77B↓ | $4.42B |
| Net Income | $2.69B↑ | -$1.65B↓ | $3.54B↑ | $2.91B↓ | $2.97B |
Peer Comparison
JNJUNHABBV
Fundamentals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$142.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.15
Beta
Defensive asset. Lower volatility than the S&P 500.
0.29
Div Yield
Strong income play. Yield provides a meaningful total return floor.
7.11%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.31%
Volume
Today's trading volume
12.78M
Recent News
66 With $1.3 Million. Here Are 3 Hidden Gems to Target
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target
China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says
Pfizer Inc. (NYSE:PFE) is among the Best Healthcare Stocks. On June 23, Reuters reported that Pfizer Inc. (NYSE:PFE) ‘s Chief International Commercial Officer, Alexandre de Germay, said China has moved ahead of Europe in pharmaceutical innovation and drug development. De Germay commented that China now has “40% of all clinical studies in oncology” globally. He pointed […]
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?
Things are going from bad to worse for the pharmaceutical giant.
Pfizer (PFE) Dismissed From Generic Drug Price Fixing Lawsuit
Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court found there was not enough evidence to support claims of Pfizer's involvement in alleged collusion. The dismissal removes a legal overhang tied to long running litigation involving multiple generic drugmakers. Pfizer is a large global pharmaceutical company with a portfolio spanning prescription medicines, vaccines, and other healthcare products. For investors...
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.